Dose Insider / Glossary / STEP 1

STEP 1The trial behind Wegovy and what it found

Updated November 20, 2026 路 3 min read 路 Wilding et al., N Engl J Med 2021; WEGOVY label

STEP 1 is the main trial behind the approval of Wegovy for weight management. It enrolled 1,961 adults with obesity, or with overweight and a weight-related condition, who did not have diabetes, and gave them semaglutide 2.4 mg or placebo once a week for 68 weeks alongside lifestyle advice. Weight fell by 14.9% on semaglutide against 2.4% on placebo.

86.4%Semaglutide 2.4 mg, 5% or more, share reaching each weight loss
Share reaching each weight lossSTEP 1, week 68, % of participantsSEMAGLUTIDE 2.4 MG5% or more86.4%10% or more69.1%15% or more50.5%PLACEBO5% or more31.5%15% or more4.9%Share reaching each weightlossSTEP 1, week 68, % of participantsSEMAGLUTIDE 2.4 MG5% or more86.4%10% or more69.1%15% or more50.5%PLACEBO5% or more31.5%15% or more4.9%

Average loss 15.3 kg on semaglutide, 2.6 kg on placebo.

On this page

The results were published in the New England Journal of Medicine in 2021.1

How the trial was run

STEP 1 was the first trial of the STEP series, which went on to test semaglutide 2.4 mg in other groups and settings. Participants had a body mass index of 30 or more, or 27 or more with at least one weight-related condition. Two in three were assigned to semaglutide and one in three to placebo. Both groups also received a lifestyle program of diet and physical activity counseling.1

The Wegovy label that grew out of these trials climbs from 0.25 mg to 2.4 mg over 16 weeks, in steps of 0.25, 0.5, 1 and 1.7 mg, four weeks each.2 The trial's main analysis counted everyone as assigned, whether or not they kept taking the drug, which makes its results closer to real use than counts limited to people who stayed on treatment.1

What it found

Wilding et al., 2021.1

The Wegovy label reports the same trial with its own counting method and gives slightly lower shares: 83.5% reaching 5% and 47.9% reaching 15%, against 31.1% and 4.8% on placebo, from a starting weight of about 105 kg.2 Both describe the same people; the gap comes from how missing data were handled. Our Wegovy weight loss chart shows how the loss builds week by week.

Side effects

Nausea and diarrhea were the most common side effects of semaglutide, usually short-lived, mild to moderate, and easing with time. Stomach and gut events led 4.5% on semaglutide to stop treatment, against 0.8% on placebo.1 Across the Wegovy weight trials, nausea was reported by 44% on the drug against 16% on placebo.2 Our page on nausea on a GLP-1 covers what helps.

Why it matters

Liraglutide 3 mg, the earlier GLP-1 medicine for weight, lowered weight by 7.4% against 3.0% on placebo over 56 weeks in its own trial, a difference of 4.4 points.3 STEP 1 nearly tripled the difference over placebo, to 12.4 points, with a weekly rather than daily injection, and it set the benchmark that later trials, including those of tirzepatide, are measured against.

It also left a question that later STEP trials took up: what happens when people stop. STEP 4 tested stopping after 20 weeks: from week 20 to week 68, people who stayed on semaglutide lost another 7.9%, while those switched to placebo regained 6.9%.4 STEP 2 tested the same dose in 1,210 people with type 2 diabetes, where weight fell by 9.6% against 3.4% on placebo, a smaller loss than without diabetes.5

Limits

The trial was funded by Novo Nordisk, the maker of semaglutide, and it excluded people with diabetes. Like most weight trials it lasted just over a year, so it cannot show what happens over many years of use.1

Sources

  1. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med 2021;384:989-1002. Funded by Novo Nordisk; NCT03548935. doi:10.1056/NEJMoa2032183
  2. WEGOVY (semaglutide) prescribing information, NDA 215256/S-025, revised June 2026. U.S. Food and Drug Administration; sections 2, 6.1 and 14. accessdata.fda.gov
  3. SAXENDA (liraglutide) injection prescribing information. Novo Nordisk; DailyMed, version published June 15, 2026; section 14. dailymed.nlm.nih.gov
  4. Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity (STEP 4). JAMA 2021;325:1414-1425. doi:10.1001/jama.2021.3224
  5. Davies M, F忙rch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet 2021;397:971-984. doi:10.1016/S0140-6736(21)00213-0

Related analyses

Log your weight weekly and see how your curve compares with the trial's.

Open Dose Insider